FINWIRES · TerminalLIVE
FINWIRES

阿達尼綠色能源公司能源產量提升34%,產能擴大至19.3吉瓦

-- 阿達尼綠色能源公司(Adani Green Energy,簡稱AGEL)週五公佈了第四季度財報,數據顯示,2026財年總能源銷量年增34%,達到375.67億千瓦時。 公司營運產能年增35%,達到19.3吉瓦,可望實現50吉瓦的目標。 AGEL表示,2026財年新增5.1吉瓦再生能源裝置容量,涵蓋太陽能、風能和混合能源項目,而2025財年為3.3吉瓦。 AGEL新增太陽能裝置容量超過3.4吉瓦,新增風能裝置容量683兆瓦,並開發了近956兆瓦的混合能源裝置容量,主要分佈在古吉拉特邦和拉賈斯坦邦。 AGEL也表示,公司超額完成了電力合約承諾,本財年電力交付量達到購電協議承諾發電量的106%,體現了其高效的營運能力。 AGEL公司表示,其位於古吉拉特邦卡夫達(Khavda)的30吉瓦再生能源專案正在推進中,該專案佔地538平方公里,目標是在2029年實現滿載運作。 該公司表示,已在卡夫達安裝了1.4吉瓦時的電池儲能係統,並計劃在2027財年之前將儲能容量擴大到10吉瓦時以上。 阿達尼綠色能源公司表示,產能擴張使其可望實現50吉瓦再生能源的目標。 執行董事薩加爾·阿達尼(Sagar Adani)表示,該公司目前營運的19.3吉瓦計畫為超過870萬戶家庭供電,每年減少約3,600萬噸碳排放。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA